Insys reaffirms Q2 revenue guidance

|About: Insys Therapeutics, Inc. (INSY)|By:, SA News Editor

Insys Therapeutics (INSY) reaffirms its Q2 revenue guidance for Subsys (Fentanyl Sublingual Spray). Sales should exceed $52M. This represents a yoy increase of 181%. The company will report its results for the quarter on August 12 before the open.